Clinical Infrared and Raman Spectroscopy Network (CLIRSPEC)

任何疾病诊断的主要部分，尤其是各种形式的癌症，都是通过活检获得的。这包括从病人身上取出一小块组织样本或几个细胞。这些样本，无论是组织还是细胞，然后由病理学家通过光学显微镜检查。在大多数情况下，样品被染色的染料组合，以帮助获得一些对比。在大多数情况下，根据对样品的目视检查作出诊断。这一过程远非理想，因为它依赖于相关临床医生的专业知识，并受到观察者内部和内部误差的影响。最近，一些概念验证研究表明，分子光谱技术，如红外和拉曼光谱技术能够根据细胞内所含的固有化学成分区分病变细胞和非病变细胞和组织。英国处于这些发展的前沿，但如果这项技术要从概念验证阶段进入转化阶段并进入临床环境，还需要克服许多障碍。学术界认为，如果我们汇集资源，引入工业界和临床合作伙伴，共同解决这些普遍问题，我们就更有可能克服这些障碍。这项申请是为未来三年支持这样一个合作伙伴网络提供资金。

A major part of the diagnosis of any disease but particularly various forms of cancer, is obtained though a biopsy. This involves removing a small sample of tissue, or a few cells, from the patient. These samples, either tissue or cells are then examined by a pathologist looking down an optical microscope. In most cases the sample is stained with a combination of dyes to help gain some contrast. In most cases, based upon visual inspection of the sample a diagnosis is made. This process if far from ideal since it relies on the expertise of the clinician concerned as is subject to intra in inter observer error. Recently a number of proof of concept studies have shown that molecular spectroscopic techniques such as infrared and Raman are capable of distinguishing diseased from non diseased cells and tissue based upon the inherent chemistry contained within the cells. The UK is at the forefront of these developments but there are many hurdles that need to be overcome if this technology is to move from the proof of concept stage through the translational stage and into the clinical setting. It is the belief of the academic community that we are much more likely to overcome these hurdles if we pool our resources, bring in both industrial and clinical partners and work on these generic problems together. This application is for funding to support such a network of partners for the next three years.